Boehringer Ingelheim

Boehringer unveils $607M deal to land Circle's preclinical cancer program
Fierce Biotech
Wed, 10/9/24 - 09:55 am
Boehringer Ingelheim
Circle Pharma
cancer
drug development
Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status
Clinical Trials Arena
Tue, 10/8/24 - 09:56 am
Boehringer Ingelheim
MASH
clinical trials
survodutide
Weight loss gold rush: Developers vie for next blockbuster treatment
Pharmaphorum
Tue, 10/8/24 - 09:45 am
R&D
obesity
weight loss
Novo Nordisk
Eli Lilly
Roche
Boehringer Ingelheim
Boehringer Ingelheim and Veeva: A data partnership for One Medicine
Pharmaphorum
Fri, 10/4/24 - 09:18 am
Boehringer Ingelheim
Veeva
One Medicine Platform
Clinical Data
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Fierce Biotech
Mon, 09/16/24 - 10:57 am
Boehringer Ingelheim
IPF
clinical trials
nerandomilast
Boehringer Ingelheim reports positive results from trial of HER2 lung cancer drug
Clinical Trials Arena
Tue, 09/10/24 - 08:35 am
Boehringer Ingelheim
clinical trials
zongertinib
non-small cell lung cancer
Boehringer adds to cancer drug pipeline with deal for startup Nerio
BioPharma Dive
Mon, 07/29/24 - 11:01 am
Boehringer Ingelheim
M&A
Nerio Therapeutics
immuno-oncology
GoodRx teams with Boehringer on Humira biosimilar
Axios
Thu, 07/18/24 - 11:21 am
GoodRx
Boehringer Ingelheim
biosimilars
Humira
Boehringer backs Brainomix AI software for lung fibrosis
Pharmaphorum
Thu, 07/18/24 - 11:08 am
Boehringer Ingelheim
digital health
lung fibrosis
Brainomix
artificial intelligence
Boehringer Ingelheim Loses Legal Challenge to IRA in Federal Court Ruling
BioSpace
Mon, 07/8/24 - 11:38 am
Boehringer Ingelheim
Inflation Reduction Act
legal
Medicare
drug pricing
Boehringer Ingelheim and Gubra begin Phase I trial of drug candidate for obesity
Clinical Trials Arena
Tue, 07/2/24 - 11:19 am
Boehringer Ingelheim
Gubra
clinical trials
BI 3034701
obesity
With 2 planned launches, Boehringer Ingelheim looks to make a name for itself in oncology
Fierce Pharma
Mon, 06/10/24 - 06:07 pm
Boehringer Ingelheim
oncology
ASCO 2024
DDLPS
glioblastoma
Boehringer, Lilly face off in MASH at EASL
Pharmaphorum
Mon, 06/10/24 - 11:14 am
Eli Lilly
Boehringer Ingelheim
MASH
EASL
tirzepatide
survodutide
Boehringer, Zealand’s GLP-1 MASH Data ‘Unintentionally’ Published by Medical Congress Website
BioSpace
Thu, 06/6/24 - 11:48 am
Zealand Pharma
Boehringer Ingelheim
MASH
survodutide
clinical trials
Top ten biopharma R&D deals of 2024
Nature
Wed, 06/5/24 - 11:24 am
R&D
Novartis
Argo Biopharmaceutical
Roche
MOMA Therapeutics
Boehringer Ingelheim
Suzhou Ribo Life Science
Eli Lilly
Isomorphic Labs
Merus
Gilead Sciences
Novo Nordisk
Neomorph
AbbVie
Umoja Biopharma
Merck KGaA
Caris Life Sciences
Voyager Therapeutics
Boehringer outlines up to $33.6m for cancer asset from OSE Therapeutics
Clinical Trials Arena
Thu, 05/23/24 - 09:43 pm
Boehringer Ingelheim
OSE Immunotherapeutics
oncology
Boehringer pays OSE $42M to expand collab into cardio disease, grab new asset
Fierce Biotech
Wed, 05/22/24 - 11:31 am
Boehringer Ingelheim
OSE Immunotherapeutics
cardiovascular disease
solid tumors
Boehringer, Walgreens Team Up for Obesity Trial as Weight-Loss Drug Race Heats Up
BioSpace
Mon, 05/6/24 - 11:33 am
Boehringer Ingelheim
Walgreens
obesity
type 2 diabetes
clinical trials
survodutide
FDA Approval Fuels Boehringer’s Biosimilar Challenge to AbbVie’s Humira
BioSpace
Thu, 05/2/24 - 11:37 am
Boehringer Ingelheim
Cyltezo
AbbVie
Huira
FDA
biosimilars
Boehringer signs $1.3B deal with RNA biotech Ochre Bio to team up against MASH
Fierce Biotech
Mon, 04/22/24 - 11:44 am
Boehringer Ingelheim
Ochre Bio
RNA
MASH
NASH

Pages